Aligos Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Aligos Therapeutics Stock-Based Compensation Growth & History (ALGS)
Aligos Therapeutics's stock-based compensation was $5.0M for fiscal 2025.
View full Aligos Therapeutics company overviewAligos Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.0M | −$3.4M | −40.32% |
| 2024 | 2024-12-31 | $8.5M | −$4.2M | −33.20% |
| 2023 | 2023-12-31 | $12.7M | −$2.0M | −13.89% |
| 2022 | 2022-12-31 | $14.7M | $1.2M | +9.18% |
| 2021 | 2021-12-31 | $13.5M | $10.5M | +352.34% |
| 2020 | 2020-12-31 | $3.0M | $2.2M | +295.61% |
| 2019 | 2019-12-31 | $752,000 | — | — |
Aligos Therapeutics quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | $204,000 | +17.59% |
| Q1 2026 | 2026-03-31 | $1.3M | $355,000 | +37.02% |
| Q4 2025 | 2025-12-31 | $1.5M | −$247,000 | −14.49% |
| Q3 2025 | 2025-09-30 | $1.5M | −$576,000 | −28.19% |
| Q2 2025 | 2025-06-30 | $1.2M | −$896,000 | −43.58% |
| Q1 2025 | 2025-03-31 | $959,000 | −$1.7M | −63.78% |
| Q4 2024 | 2024-12-31 | $1.7M | −$878,000 | −33.99% |
| Q3 2024 | 2024-09-30 | $2.0M | −$1.2M | −36.34% |
| Q2 2024 | 2024-06-30 | $2.1M | −$1.1M | −35.67% |
| Q1 2024 | 2024-03-31 | $2.6M | −$1.0M | −27.73% |
| Q4 2023 | 2023-12-31 | $2.6M | −$833,000 | −24.39% |
| Q3 2023 | 2023-09-30 | $3.2M | −$282,000 | −8.08% |
| Q2 2023 | 2023-06-30 | $3.2M | −$804,000 | −20.10% |
| Q1 2023 | 2023-03-31 | $3.7M | −$122,000 | −3.22% |
| Q4 2022 | 2022-12-31 | $3.4M | −$235,000 | −6.44% |
| Q3 2022 | 2022-09-30 | $3.5M | −$110,000 | −3.05% |
| Q2 2022 | 2022-06-30 | $4.0M | $551,000 | +15.98% |
| Q1 2022 | 2022-03-31 | $3.8M | $1.0M | +37.37% |
| Q4 2021 | 2021-12-31 | $3.7M | $2.4M | +180.63% |
| Q3 2021 | 2021-09-30 | $3.6M | $2.6M | +254.43% |
| Q2 2021 | 2021-06-30 | $3.4M | $3.4M | +6532.69% |
| Q1 2021 | 2021-03-31 | $2.8M | $2.1M | +354.79% |
| Q4 2020 | 2020-12-31 | $1.3M | — | — |
| Q3 2020 | 2020-09-30 | $1.0M | $865,000 | +572.85% |
| Q2 2020 | 2020-06-30 | $52,000 | — | — |
| Q1 2020 | 2020-03-31 | $606,000 | — | — |
| Q3 2019 | 2019-09-30 | $151,000 | — | — |
Aligos Therapeutics stock-based compensation trends
Over the last five fiscal years, Aligos Therapeutics's stock-based compensation increased from $3.0M to $5.0M, a change of $2.1M. The latest reported quarter, Q2 2026, shows $1.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aligos Therapeutics source filings ↗